Hikal
NSE: HIKAL · Pharmaceuticals
Snapshot
Unlock Hikal's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Hikal Limited is a diversified manufacturer of chemical intermediates, specialty chemicals, and active pharmaceutical ingredients (APIs). The company operates through two primary segments: Pharmaceuticals and Crop Protection, serving global clients in the life sciences and specialty chemical sectors.
Business Model
The company generates revenue through contract research, custom synthesis, and the manufacturing of proprietary chemical products. It leverages its technical expertise to provide bespoke solutions for pharmaceutical, animal healthcare, and crop protection industries.
Growth Outlook
Growth is driven by the expansion of custom manufacturing partnerships and the increasing demand for specialty biocides across diverse industrial applications. The company continues to focus on strengthening its R&D capabilities to support long-term client collaborations.
Key Risks
- Regulatory Compliance. The company is subject to stringent global regulatory standards for pharmaceutical manufacturing, where non-compliance could lead to product recalls or facility bans.
- Raw Material Price Volatility. Fluctuations in the cost of chemical feedstocks and intermediates can significantly impact operating margins.
- Environmental and Safety Risks. As a chemical manufacturer, the company faces risks related to environmental regulations, waste management, and industrial safety protocols.
- Client Concentration. Dependence on a limited number of large-scale contract manufacturing clients may create revenue volatility if key partnerships are terminated.
Start your research today
Unlock AI insights, financials, peers and live data on Hikal and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,735 Cr
TTM · consolidated
NET PROFIT
₹-34 Cr
TTM · consolidated
EPS
₹-2.74
TTM · consolidated
RETURN ON EQUITY
-2.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
0.1%
TTM · consolidated
P/E
-78.3×
Q1 FY27 · consolidated
EV/EBITDA
13.5x
Q1 FY27 · consolidated
EBITDA MARGIN
14.1%
TTM · consolidated
NET PROFIT MARGIN
-1.8%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.5%
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
HikalHIKAL | ₹2,645 Cr | -78.3× | 13.52 | -5.4% | 14.1% | -2.7% | 0.1% | -12.0% |
Solara Active Pharma Sciences LimitedSOLARA | ₹3,027 Cr | 82.2× | 14.78 | 27.3% | 15.7% | 2.7% | 8.1% | -0.3% |
Ind-Swift Laboratories LimitedINDSWFTLAB | ₹2,989 Cr | 35.2× | 17.94 | 66.4% | 19.8% | 6.0% | 7.4% | +236.3% |
Fredun Pharmaceuticals LimitedFREDUN | ₹2,405 Cr | 17.5× | 23.24 | — | 14.9% | 20.9% | 39.1% | -6.4% |
Dishman Carbogen Amcis LimitedDCAL | ₹2,369 Cr | 146.7× | 8.15 | 0.2% | 18.4% | 0.3% | 2.1% | -48.3% |
Sakar HealthcareSAKAR | ₹2,102 Cr | 58.3× | 26.67 | 43.8% | 29.7% | 11.8% | 15.6% | +153.8% |
As of Q1 FY27
Financials
Hikal
NSE: HIKAL · Pharmaceuticals
Snapshot
Unlock Hikal's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Hikal Limited is a diversified manufacturer of chemical intermediates, specialty chemicals, and active pharmaceutical ingredients (APIs). The company operates through two primary segments: Pharmaceuticals and Crop Protection, serving global clients in the life sciences and specialty chemical sectors.
Business Model
The company generates revenue through contract research, custom synthesis, and the manufacturing of proprietary chemical products. It leverages its technical expertise to provide bespoke solutions for pharmaceutical, animal healthcare, and crop protection industries.
Growth Outlook
Growth is driven by the expansion of custom manufacturing partnerships and the increasing demand for specialty biocides across diverse industrial applications. The company continues to focus on strengthening its R&D capabilities to support long-term client collaborations.
Key Risks
- Regulatory Compliance. The company is subject to stringent global regulatory standards for pharmaceutical manufacturing, where non-compliance could lead to product recalls or facility bans.
- Raw Material Price Volatility. Fluctuations in the cost of chemical feedstocks and intermediates can significantly impact operating margins.
- Environmental and Safety Risks. As a chemical manufacturer, the company faces risks related to environmental regulations, waste management, and industrial safety protocols.
- Client Concentration. Dependence on a limited number of large-scale contract manufacturing clients may create revenue volatility if key partnerships are terminated.
Start your research today
Unlock AI insights, financials, peers and live data on Hikal and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,735 Cr
TTM · consolidated
NET PROFIT
₹-34 Cr
TTM · consolidated
EPS
₹-2.74
TTM · consolidated
RETURN ON EQUITY
-2.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
0.1%
TTM · consolidated
P/E
-78.3x
Q1 FY27 · consolidated
EV/EBITDA
13.5x
Q1 FY27 · consolidated
EBITDA MARGIN
14.1%
TTM · consolidated
NET PROFIT MARGIN
-1.8%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.5%
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27